Home » Topics » BioWorld Science

BioWorld Science
RSS

European Commission approves Xospata for relapsed or refractory FLT3 mutation-positive AML

Oct. 25, 2019

FDA approves Baxdela for community-acquired bacterial pneumonia

Oct. 25, 2019

NIAID awards contract to UAB to study Bexsero for gonorrhea prevention

Oct. 25, 2019

New phase I trial investigates MB-108 in recurrent glioblastoma multiforme

Oct. 25, 2019

Syros reports new data from phase II trial of SY-1425 in newly diagnosed unfit AML

Oct. 25, 2019

Japan Tobacco describes new SLC5A1 inhibitors

Oct. 25, 2019

Merck KGaA synthesizes new IRAK inhibitors

Oct. 25, 2019

AbbVie and Galapagos identify mutant CFTR correctors for cystic fibrosis

Oct. 25, 2019

Janssen Pharmaceutica presents new ionotropic glutamate GluN2B receptor antagonists

Oct. 25, 2019

Aurigene Discovery Technologies divulges CDK12 and CDK13 inhibitors

Oct. 25, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...